Cargando…

Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux(® )and particle therapy]

BACKGROUND: Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent leading to the establishment of particle therapy in this indication. However, even modern techniques leave space for improvement of local control by intensification of local treatment. Rad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Alexandra D, Nikoghosyan, Anna, Hinke, Axel, Debus, Jürgen, Münter, Marc W
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042975/ https://www.ncbi.nlm.nih.gov/pubmed/21320355 http://dx.doi.org/10.1186/1471-2407-11-70

Ejemplares similares

Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck
por: Jensen, A D, et al.
Publicado: (2019)

Severe Acneiform Eruption Induced by Cetuximab (Erbitux®)
por: Lee, Jung Eun, et al.
Publicado: (2008)

Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the treatment of incompletely and completely resected adenoid cystic carcinomas of the head and neck: initial clinical results and toxicity of treatment
por: Münter, MW, et al.
Publicado: (2006)

RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab
por: Jensen, Alexandra D, et al.
Publicado: (2010)

Treatment of malignant sinonasal tumours with intensity-modulated radiotherapy (IMRT) and carbon ion boost (C12)
por: Jensen, Alexandra D, et al.
Publicado: (2011)

IMRT and carbon ion boost for malignant salivary gland tumors: interim analysis of the COSMIC trial
por: Jensen, Alexandra D, et al.
Publicado: (2012)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Immunologic profiling of adenoid cystic carcinoma (acc)
por: Sridharan, Vishwajith, et al.
Publicado: (2015)

Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity
por: Lang, Kristin, et al.
Publicado: (2018)

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
por: Jensen, Alexandra D, et al.
Publicado: (2010)

Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol
por: Habl, Gregor, et al.
Publicado: (2010)

Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT
por: Jensen, Alexandra D, et al.
Publicado: (2011)

Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series
por: Bernhardt, Denise, et al.
Publicado: (2018)

Genetic Profiling Reveals Cross-Contamination and Misidentification of 6 Adenoid Cystic Carcinoma Cell Lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2
por: Phuchareon, Janyaporn, et al.
Publicado: (2009)

Genetic Profile of Adenoid Cystic Carcinomas (ACC) with High-Grade Transformation versus Solid Type
por: Costa, Ana Flávia, et al.
Publicado: (2010)

Advanced adenoid cystic carcinoma (ACC) is featured by SWI/SNF chromatin remodeling complex aberrations
por: Jagielska, Beata, et al.
Publicado: (2018)

Adenoid Cystic Carcinoma (ACC) of the Bartholin's gland misdiagnosed for three times: a case report
por: Alhashemi, Moustafa, et al.
Publicado: (2023)

Treatment Outcome of 227 Patients with Sinonasal Adenoid Cystic Carcinoma (ACC) after Intensity Modulated Radiotherapy and Active Raster-Scanning Carbon Ion Boost: A 10-Year Single-Center Experience
por: Akbaba, Sati, et al.
Publicado: (2019)

Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial
por: Jensen, Alexandra D, et al.
Publicado: (2012)

Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial
por: Habl, G, et al.
Publicado: (2013)

Persistence of radiation-induced aberrations in patients after radiotherapy with C-ions and IMRT
por: Hartel, Carola, et al.
Publicado: (2018)

Dosimetric Comparison of the Simultaneous Integrated Boost in Whole-Breast Irradiation after Breast-Conserving Surgery: IMRT, IMRT plus an Electron Boost and VMAT
por: Wu, Sangang, et al.
Publicado: (2015)

Possible local treatment for liver metastases of adenoid cystic carcinoma (ACC): single-centre experience and literature review
por: Zheng, Yiling, et al.
Publicado: (2020)

Unusual presentation of adenoid cystic carcinoma (ACC) on lip mimicking mucocele: A rare case report with review
por: Majumder, Dipen, et al.
Publicado: (2023)

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)

Dominant Gene Expression Profiles Define Adenoid Cystic Carcinoma (ACC) from Different Tissues: Validation of a Gene Signature Classifier for Poor Survival in Salivary Gland ACC
por: Brayer, Kathryn J., et al.
Publicado: (2023)

Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma
por: Shirasaki, Takashi, et al.
Publicado: (2008)

Dosimetric and Clinical Risk Factors for the Development of Maxillary Osteoradionecrosis in Adenoid Cystic Carcinoma (ACC) Patients Treated With Carbon Ion Radiotherapy
por: Vischioni, Barbara, et al.
Publicado: (2022)

Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response
por: Bhuvaneswari, Ramaswamy, et al.
Publicado: (2009)

Adenoid cystic carcinoma of palate
por: Mehta, Dhaval N., et al.
Publicado: (2013)

Dedifferentiation in adenoid cystic carcinoma
por: Bavle, Radhika M, et al.
Publicado: (2013)

Adenoid cystic carcinoma of the breast
por: Thomas, Devon N, et al.
Publicado: (2019)

Adenoid Cystic Carcinoma of Mandible
por: Santos, Thiago de Santana, et al.
Publicado: (2015)

Successful Treatment of Adenoid Cystic Carcinoma with the Application of a High-Dose Stereotactic Body Radiotherapy Boost
por: Polanowski, Paweł, et al.
Publicado: (2021)

Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case–control study
por: Wu, Xin, et al.
Publicado: (2016)

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial
por: Hitre, E, et al.
Publicado: (2013)

Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx
por: Hauswald, H., et al.
Publicado: (2018)

Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial
por: Liermann, Jakob, et al.
Publicado: (2022)

Adenoid cystic carcinoma of the parotid gland
por: Godge, Pournima, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t689epp4b0dhtthv0bmtd09j51